Springlane

SpringWorks Therapeutics is a commercial-stage biopharmaceutical company focused on developing precision medicines for rare diseases and cancer. The company's lead product, OGSIVEO (nirogacestat), is the first FDA-approved therapy for adult patients with progressing desmoid tumors. SpringWorks is also advancing mirdametinib, a MEK inhibitor, for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) in both pediatric and adult patients. Their diversified pipeline includes several targeted oncology programs, such as TEAD inhibitors and combinations with BCMA-targeted therapies for multiple myeloma. The company utilizes a precision medicine approach, often collaborating with major pharmaceutical companies like Pfizer and GSK to maximize the potential of its therapeutic candidates.